PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

IGF-1 (Mecasermin / recombinant human IGF-1) — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Mecasermin is recombinant human IGF-1; it is the only treatment for severe primary IGF-1 deficiency (growth hormone insensitivity), approved in the United States in 2005 and in Europe in 2007. · pmid:19707272

In a phase 1 study in 12 girls with MECP2 mutations (9 with Rett syndrome), mecasermin reached the cerebrospinal fluid without hypoglycemia or serious adverse events, and apnea and some mood and anxiety measures improved in the open-label extension. · pmid:24623853

Identity

No public registry record is shown for this page: PubChem gave no record that proves it is this substance.

Where the evidence actually sits

Established50%
Emerging50%

Proportion of the 2 claims about IGF-1 (Mecasermin / recombinant human IGF-1) standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. (2009) · establishedSafety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. (2014) · emerging20092014

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for IGF-1 (Mecasermin / recombinant human IGF-1) yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. · pmid 19707272 · 2009
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested
    • Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. · pmid 24623853 · 2014
  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.